Navigation Links
Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders' Equity Deficiency
Date:5/15/2008

AMEX's $6 million stockholders' equity threshold required for continued listing under AMEX Rule 1003(a)(iii). This notification was triggered by the decline of Signalife's market capitalization to less than $50 million, which previously exempted Signalife from meeting the minimum stockholders' equity requirement. In response to the letter, Signalife submitted to AMEX for its review and acceptance a plan to bring the company into compliance with the aforesaid stockholders' equity requirement. On March 20, 2008, AMEX notified Signalife that it accepted the company's plan of compliance and granted the company an extension until May 7, 2009 to regain compliance with the aforesaid stockholders' equity requirement. On May 14, 2008, Signalife received a second deficiency letter from the American Stock Exchange ("AMEX") pursuant to which it advised that Signalife would also need to comply with AMEX's $4 million stockholders' equity threshold required for continued listing under AMEX Rule 1003(a)(ii). In that letter, AMEX advised Signalife that should it desire to do so, the company could supplement its pending plan of compliance to address this new deficiency. Signalife believes that its pending plan of compliance will have equal applicability to the new deficiency cited, and has notified AMEX that it will be supplementing its pending plan of compliance to address this new issue. No guarantee can be given that AMEX will accept the plan as supplemented or that Signalife will be able to so increase its stockholders' equity to the $4 million threshold within the period stipulated by AMEX, either of which would lead to a delisting of Signalife's common shares from the AMEX market.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies t
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
2. Signalife Announces Webcast
3. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
4. Signalife Sees Accretive Purchase and Financial Commitments
5. Signalife Wins Second Frost & Sullivan Technology Award
6. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
7. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
8. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
9. U.S. Patent 7,299,083 Awarded to Signalife
10. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
11. Signalife Continues to Procure Purchase Orders, Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... ... Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use ... Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound. ...
(Date:8/27/2015)... Aug. 27, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced ... I study of BHV-0223, a glutamate modulating agent. ... BHV-0223 and recently obtained clearance from the U.S. ... human testing. Portage holds 54% equity interest in ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
Breaking Biology Technology:Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3
... 3 The Connecticut Technology,Council and UHY LLP is ... Connecticut. The list of winning companies, called the UHY ... revenue growth over the last four,years. Companies considered for ... of the public companies winning this year exceeding,$1Billion in ...
... MS, EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... U.S. pivotal phase III MAESTRO-03 trial of dirucotide ... a safety analysis,and recommended that the trial continue ...
... for Ap3ana, CTI,s ,personalized medicine, venture, SEATTLE, ... CTIC ) announced today that Christina A. Waters, ... Tyr Pharma and formerly Director of,Scientific Development at ... named President of CTI Europe. Based in Bresso, ...
Cached Biology Technology:Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners 2BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... promising on paper; things are,often very different in reality. ... are supposed to strip the "immortal" (able to,divide indefinitely) ... to block their function, preventing them to inhibit completely,the ... for something,else? Hell no! Look out for whats stopping ...
... Notch pathway ,is an important molecular signaling mechanism whose ... nearly a century since the,identification of a mutant strain ... lab in 1910. Later studies,revealed that the Notch gene ... the cell membrane and which is capable of,interacting with ...
Cached Biology News:GATA: a graphic alignment tool for comparative sequence analysis 2Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
Form: Concentrated Applications: ELISA...
Form: Concentrated Applications: ELISA...
ANTI S. GROUP AG:H...
... Flp-In System creates isogenic cell lines ... of the protein of interest. This ... 3. In this experiment the coding ... subcloned into pcDNA5/FRT and transfected into ...
Biology Products: